

Schering-Plough Animal Health Corporation 556 Morris Avenue Summit, NJ 07901

MATERIAL SAFETY DATA SHEET

Schering-Plough urges each user or recipient of this MSDS to read the entire data sheet to become aware of the hazards associated with this material.

SECTION 1. IDENTIFICATION OF SUBSTANCE AND CONTACT INFORMATION

MSDS NAME: Covexin 8

SYNONYM(S): Tasvax 8

Clostridium chauvoei, C. septicum, C. haemolyticum, C. novyi, C. tetani, C. perfringens Type C and C.

perfringens Type D

Clostridium chauvoei, C. septicum, C. haemolyticum, C. novyi, C. tetani, C. perfringens Type B, C.

perfringens Type C, and C. perfringens Type D

MSDS NUMBER: SP000714

EMERGENCY NUMBER(S): Schering-Plough Security Control Center (908) 820-6921 (24 hours)

Transportation Emergencies - CHEMTREC: (800) 424-9300 (Inside Continental USA) (703) 527-3887 (Outside Continental USA)

Rocky Mountain Poison Center (For Human Exposure):

(303) 595-4869

Animal Health Technical Services:

For Animal Adverse Events: Small Animals and Horses: (800) 224-5318

For Animal Adverse Events: Livestock: (800) 211-3573 For Animal Adverse Events: Poultry: (800) 219-9286

INFORMATION: Animal Health Technical Services:

For Small Animals and Horses: (800) 224-5318

For Livestock: (800) 211-3573 For Poultry: (800) 219-9286

SCHERING-PLOUGH MSDS HELPLINE: (800) 770-8878 (US and Canada)

(908) 629-3657 (Worldwide)

Monday to Friday, 9am to 5pm (US Eastern Time)

SECTION 2. HAZARDS IDENTIFICATION

EMERGENCY OVERVIEW

Light Brown, Amber

Liquid

Odor unknown

May be irritating to eyes, skin or respiratory tract.

May cause allergic reactions in susceptible individuals.

May cause effects to:

- gastrointestinal tract
- liver
- kidney

Covexin 8 MSDS NUMBER: SP000714

Latest Revision Date: 18-Nov-2005 Page 1 of 5 Published Date: 18-Nov-2005

POTENTIAL HEALTH EFFECTS:

ADDITIONAL INFORMATION:

The toxicological properties of the mixture(s) have not been fully characterized in humans or animals. However, there are data to describe the toxicological properties of the individual ingredients. The following summary is based upon available information about the individual ingredients of the mixture(s), or of the expected properties of the mixture(s). Only information about the ingredients that are expected to contribute significantly to the potential health hazard profile of the formulation(s) is presented.

This product is a vaccine for use in animals. As with any vaccine, exposure may cause hypersensityity reactions. Pathogenic clostridia bactrial strains may cause infection to damaged skin.

Potassium aluminum sulfate dodecahydrate, an ingredient in this product, is an astringent (causes contraction of the tissues). This material is a mucous membrane irritant and a neurotoxic agent when absorbed systemically. Inhalation of dust or mist causes irritation to the eyes, nose, mouth, and respiratory tract. Prolonged dermal contact may cause a numbing sensation in the fingers. Ingestion of this material may cause cramping, nausea, vomiting and bleeding and inflammation of the mucous membrane of the stomach and intestine. Acute exposure to potassium aluminum sulfate dodecahydrate has been reported to cause liver damage following acute and chronic exposure, as well as, liver and renal necrosis in animal studies.

LISTED CARCINOGENS

Not listed as a carcinogen by OSHA, IARC, NTP or ACGIH.

This product contains a preservative or preservatives which may cause allergic-type reactions, including

anaphylactic shock, in susceptible individuals.

SECTION 3. COMPOSITION AND INFORMATION ON INGREDIENTS

PRODUCT USE: Vaccine **CHEMICAL FORMULA:** Mixture.

The formulations for these products are proprietary information. These formulations have the same hazardous profile; however, the presence of hazardous ingredients may vary by formulation. Only hazardous ingredients in concentrations of 1% or greater and/or carcinogenic ingredients in concentrations of 0.1% or greater are listed in the Chemical Composition table. Active ingredients in any concentration are listed. For additional information about carcinogenic ingredients see Section 3.

The product(s) may contain preservatives, as listed, in concentrations less than 1%.

CHEMICAL COMPOSITION

CHEMICAL NAME	CAS NUMBER	PERCENT
C. haemolyticum toxoid (inactivated)		< 10
C. septicum toxoid (inactivated)		< 10
C. tetani toxoid (inactivated)		< 1
C. perfringens Type B toxoid (inactivated)		< 1
C. perfringens Type C toxoid (inactivated)		<1
C. perfringens Type D toxoid (inactivated)		<1
Potassium aluminium sulfate dodecahydrate	7784-24-9	< 10
C. chauvoei whole cell culture (inactivated)		< 10
C. novyi Type B toxoid (inactivated)		< 10
Preservative (Thiomersal)		< 1

ADDITIONAL INFORMATION:

This MSDS is written to provide health and safety information for individuals who will be handling the final product formulation during research, manufacturing, and distribution. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate MSDS for each ingredient. Refer to the package insert or product label for handling guidance for the consumer.

SECTION 4. FIRST AID MEASURES

INHALATION: Remove to fresh air. If any trouble breathing, get immediate medical attention. Administer artificial respiration if breathing has ceased. If irritation or symptoms occur or persist, consult a physician.

SKIN CONTACT: In case of skin contact, while wearing protective gloves, carefully remove any contaminated clothing, including shoes, and wash skin thoroughly with soap and water. If irritation or symptoms occur or persist,

consult a physician.

EYE CONTACT: In case of eye contact, immediately rinse eyes thoroughly with plenty of water. If wearing contact lenses, remove only after initial rinse, and continue rinsing eyes for at least 15 minutes. If irritation occurs or

persists, consult a physician.

Covexin 8 MSDS NUMBER: SP000714

Latest Revision Date: 18-Nov-2005 Page 2 of 5 Published Date: 18-Nov-2005 INGESTION: Rinse mouth and drink a glass of water. Do not induce vomiting unless under the direction of a qualified

medical professional or Poison Control Center. If symptoms persist, consult a physician.

NOTE TO PHYSICIAN: This product is a vaccine. Accidental injection may cause necrosis or vascular spasm. This preparation

contains a preservative or antibiotic or both which may cause allergic reactions in susceptible individuals.

SECTION 5. FIRE FIGHTING MEASURES

FLAMMABILITY DATA:

Flash Point: Not determined (liquids) or not applicable (solids).

SPECIAL FIRE FIGHTING PROCEDURES:

Wear full protective clothing and self-contained breathing apparatus (SCBA).

SUITABLE EXTINGUISHING MEDIA:

Carbon dioxide (CO2), extinguishing powder or water spray.

See Section 9 for Physical and Chemical Properties.

SECTION 6. ACCIDENTAL RELEASE MEASURES

PERSONAL PRECAUTIONS:

Keep personnel away from the clean-up area. Wear appropriate personal protective equipment as specified in Section 8.

SPILL RESPONSE / CLEANUP:

Notify Emergency Spill Response Team if spill is greater than one liter or worker is uncomfortable with clean up procedure.

For small spills, treat with disinfectant such as diluted (5% v/v) chlorine bleach. Use protective gloves, lab coat and eye protection. For larger spills, leave room, closing door behind. Allow aerosols to settle for at least 15 minutes. Re-enter room and absorb spilled liquid with paper towels. Wash contaminated area with disinfectant such as diluted (5% v/v) chlorine bleach. Place all spill residue in a double plastic bag and seal. Dispose of spill residue in accordance with federal, state, and local waste disposal regulations.

ENVIRONMENTAL PRECAUTIONS:

Do not allow product to reach ground water, water course, sewage or drainage systems.

See Sections 9 and 10 for additional physical, chemical, and hazard information.

SECTION 7. HANDLING AND STORAGE

HANDLING:

Ensure adequate ventilation. Handle in essentially closed systems, or in a laboratory fume hood. Cover containers during material transfer or transportation.

STORAGE

Store between 2 and 8 deg C. Do not freeze. Store out of direct sunlight.

See Section 8 for exposure controls and additional safe handling information.

SECTION 8. EXPOSURE CONTROLS AND PERSONAL PROTECTION

EXPOSURE CONTROLS:

The health hazard risks of handling this material are dependent on many factors, including physical form, duration and frequency of process or task, and effectiveness of engineering controls. Site-specific risk assessments should be conducted to determine the feasibility and the appropriateness of all exposure control measures. Exposure controls for normal operating or routine procedures follow a tiered strategy. Engineering controls are the preferred means of long-term or permanent exposure control. If engineering controls are not feasible, appropriate use of personal protective equipment (PPE) may be considered as alternative control measures. However, PPE should not be used as a method of permanent or long-term exposure control. Exposure controls for non-routine operations must be evaluated and addressed as part of the site-specific risk assessment.

RECOMMENDED PERSONAL PROTECTIVE EQUIPMENT (PPE):

Covexin 8 MSDS NUMBER: SP000714

Latest Revision Date: 18-Nov-2005 Page 3 of 5 Published Date: 18-Nov-2005

Respiratory Protection: In laboratories and small-scale operations, respirators are not normally required; however, appropriate

respiratory protection may be required in situations where exposure (e.g. spills, process upsets, or non-routine maintenance) may exceed any available recommended exposure limit. Consult your site safety

staff for guidance.

In manufacturing and large-scale operations, powered air purifying respirators (PAPRs) or positivepressure air supplied respirators with full-face coverage may be required dependent on the level of exposure. Appropriate respiratory protection is required in situations where exposure (e.g. spills, process upsets, or non-routine maintenance) may exceed any available recommended exposure limit. Consult your

site safety staff for guidance.

Skin Protection: Gloves that provide an appropriate barrier to the skin are recommended if there is potential for contact with

this material. Consult your site safety staff for guidance.

Eye Protection: Safety glasses with side shields. Use of goggles or full face protection may be required based on hazard,

potential for contact, or level of exposure. Consult your site safety staff for guidance.

Body Protection: In small-scale or laboratory operations, lab coats or equivalent protection is required. Disposable Tyvek or

other dust impermeable suit should be considered based on procedure or level of exposure. Use of additional PPE such as shoe coverings, gauntlets, hood, or head covering may be necessary. Consult

your site safety staff for guidance.

In large-scale or manufacturing operations, disposable Tyvek or other dust impermeable suit is

recommended and based on level of exposure. Use of additional PPE such as shoe coverings, gauntlets,

hood, or head covering may be necessary. Consult your site safety staff for guidance.

EXPOSURE LIMIT VALUES

No exposure limits are available for the active ingredient(s) or any other hazardous ingredient in this formulation.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

FORM: Liquid

COLOR: Light Brown, Amber ODOR: Odor unknown

SOLUBILITY:

Water: Forms a suspension with water

See Section 5 for flammability/explosivity information.

SECTION 10. STABILITY AND REACTIVITY

STABILITY/ REACTIVITY:

Stable under normal conditions.

INCOMPATIBLE MATERIALS / CONDITIONS TO AVOID:

Avoid high temperatures.

HAZARDOUS DECOMPOSITION PRODUCTS / REACTIONS:

No dangerous decomposition is expected if used according to manufacturer's specifications.

SECTION 11. TOXICOLOGICAL INFORMATION

The toxicological properties of this material have not been characterized in humans or animals. The information presented below pertains to the following individual ingredients, and not to the mixture(s).

ACUTE TOXICITY DATA

INHALATION:

Potassium aluminum sulfate dodecahydrate: Irritating to mucous membrane and respiratory tract.

SKIN:

Potassium aluminum sulfate dodecahydrate: Irritating.

EYE:

Potassium aluminum sulfate dodecahydrate: Irritating.

ORAL:

Potassium aluminum sulfate dodecahydrate: Oral LD50: 4210 to 6207 mg/kg (mouse); 1930 mg/kg (rat)

Covexin 8 MSDS NUMBER: SP000714

Latest Revision Date: 18-Nov-2005 Page 4 of 5 Published Date: 18-Nov-2005

REPEAT DOSE TOXICITY DATA

MUTAGENICITY / GENOTOXICITY:

Rats administered anhydrous potassium aluminum sulfate for up to 21 days at oral dose levels as high as 764 mg/kg/day exhibited an increased incidence of chromosome aberrations in bone marrow cells.

CARCINOGENICITY:

This material or product has not been evaluated for carcinogenicity.

Mice administered anhydrous potassium aluminum sulfate at concentrations up to 10% in their diet for 20 months did not exhibit an increase in tumor incidences nor where there any other signs of toxicity noted.

SECTION 12. ECOLOGICAL INFORMATION

ECOTOXICITY DATA

There are no ecototoxicity data available for this product or its components.

ENVIRONMENTAL DATA

There are no environmental data available for this product or its components.

SECTION 13. DISPOSAL CONSIDERATIONS

MATERIAL WASTE:

Disposal must be in accordance with applicable federal, state/provincial, and/or local regulations. Incineration is the preferred method of disposal, when appropriate. Operations that involve the crushing or shredding of waste materials or returned goods must be handled to meet the recommended exposure limit(s).

PACKAGING AND CONTAINERS:

Disposal must be in accordance with applicable federal, state/provincial, and/or local regulations.

SECTION 14. TRANSPORT INFORMATION

This material is not subject to the transportation regulations of DOT, ICAO, IMO, and the ADR.

SECTION 15. REGULATORY INFORMATION

TSCA LISTING

This material or product is not subject to TSCA requirements.

U.S. STATE REGULATIONS

Check state requirements for ingredient listing.

SECTION 16. OTHER INFORMATION

Although reasonable care has been taken in the preparation of this document, we extend no warranties and make no representations as to the accuracy or completeness of the information contained therein, and assume no responsibility regarding the suitability of this information for the user's intended purposes or for the consequence of its use. Each individual should make a determination as to the suitability of the information for their particular purpose(s).

DEPARTMENT ISSUING MSDS: Global Safety and Environmental Affairs

Occupational and Environmental Toxicology

Schering-Plough Corporation

1095 Morris Avenue

Union, NJ 07083 USA

SCHERING-PLOUGH MSDS HELPLINE: (800) 770-8878 (US and Canada)

(908) 629-3657 (Worldwide)

Monday to Friday, 9am to 5pm (US Eastern Time)

MSDS CREATION DATE: 23-May-1986 SUPERSEDES DATE: 20-Oct-2003

Covexin 8 MSDS NUMBER: SP000714

Latest Revision Date: 18-Nov-2005 Page 5 of 5 Published Date: 18-Nov-2005